Non-segmental Vitiligo study: SHR0302 Tablets vs SHR0302 Base Gel
Official title A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo
ClinicalTrials.gov ID: NCT07251595
What this study is testing
What is SHR0302 Tablets?
An investigational oral tablet being studied as a potential treatment for non‑segmental vitiligo.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will see how well SHR0302 tablets alone or with a base gel work and how safe they are for treating non‑segmental vitiligo.
- Who it's for
- Adults who have non‑segmental vitiligo and meet the study’s eligibility criteria.
- What's involved
- Participants may receive SHR0302 tablets, the gel, or both, and will have regular visits for medical checks and skin assessments.
- Time commitment
- The trial lasts several months, with scheduled clinic visits for medication use, safety monitoring, and skin evaluations.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Sign the informed consent form before the clinical trial.
- On the day of signing the informed consent form, the age must be between 18 and 75 years old (inclusive), and it can be either male or female.
- The people and their partners had no intention of having children during the study period and within one month after the administration of the drug...
- During the screening process, it was clinically diagnosed as non-segmental vitiligo.
- Throughout the entire research process, the participants agreed to stop using all treatments related to vitiligo as well as any cosmetic products...
You likely can't join if
- people diagnosed with segmental, mixed or undifferentiated vitiligo; or people previously diagnosed with other skin pigmentation disorders.
- When the facial skin lesions caused by vitiligo cover more than 33% of the area with white hair.
- During the screening period or at the baseline, there were other active skin lesions or skin infections that might interfere with the use of the...
- people with a history of related infections/communicable diseases or infection/contagion history.
- Known or suspected history of immunosuppression.
- Tuberculosis (TB) or latent tuberculosis infection.
See the full eligibility criteria
- Sign the informed consent form before the clinical trial.
- On the day of signing the informed consent form, the age must be between 18 and 75 years old (inclusive), and it can be either male or female.
- The people and their partners had no intention of having children during the study period and within one month after the administration of the drug, did not donate sperm or eggs, and voluntarily adopted effective...
- During the screening process, it was clinically diagnosed as non-segmental vitiligo.
- Throughout the entire research process, the participants agreed to stop using all treatments related to vitiligo as well as any cosmetic products with therapeutic effects.
- people diagnosed with segmental, mixed or undifferentiated vitiligo; or people previously diagnosed with other skin pigmentation disorders.
- When the facial skin lesions caused by vitiligo cover more than 33% of the area with white hair.
- During the screening period or at the baseline, there were other active skin lesions or skin infections that might interfere with the use of the study drug or the evaluation of the drug's how well it works.
- people with a history of related infections/communicable diseases or infection/contagion history.
- Known or suspected history of immunosuppression.
- Tuberculosis (TB) or latent tuberculosis infection.
- Positive for human immunodeficiency virus antibody HIV-Ab, positive for syphilis-specific antibody, positive for hepatitis C virus antibody HCV-Ab, or hepatitis B virus (HBV) infection.
- people who have malignant tumors or have a history of malignant tumors.
- Abnormal thyroid function, with a history of thrombotic diseases within the previous 12 months, and having experienced a cardiovascular or cerebrovascular event that required hospitalization within the previous 12...
- There are serious abnormalities in the cardiovascular, mental, renal, liver, immune, gastrointestinal, urogenital, nervous, skeletal-muscular, skin, sensory, endocrine or hematological systems.
- Pregnant women, lactating women, or female participants who plan to become pregnant during the study period.
- Those who are known to be allergic to the test drug or any component of the test drug.
The study team makes the final eligibility decision.
Where it is enrolling
- Jinan, Shandong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Jinan, Shandong, China. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.